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Chimeric antigen receptor (CAR) T cell therapy is routinely used to treat patients with
refractory hematologic malignancies. However, a signiﬁcant proportion of patients experience
suboptimal CAR T cell cytotoxicity and persistence that can permit tumor cell escape and
disease relapse. Here we show that a prototype pro-lymphoid growth factor is able to
enhance CAR T cell efﬁcacy. We demonstrate that a long-acting form of recombinant human
interleukin-7 (IL-7) fused with hybrid Fc (rhIL-7-hyFc) promotes proliferation, persistence
and cytotoxicity of human CAR T cells in xenogeneic mouse models, and murine CAR T cells
in syngeneic mouse models, resulting in long-term tumor-free survival. Thus, rhIL-7-hyFc
represents a tunable clinic-ready adjuvant for improving suboptimal CAR T cell activity.
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C

himeric antigen receptor (CAR) T cell therapy is transforming modern cancer therapy, with four anti-CD19
CAR T cell products Food and Drug Administrationapproved for relapsed/refractory B cell malignancies1–4, and
many other CAR T cells for a variety of tumors currently being
tested in clinical trials. However, in clinical practice suboptimal
CAR T cell efﬁcacy often results in antigen-positive tumor escape
and disease relapse5,6. As the expansion and persistence of CAR
T cells correlate with clinical response, we reasoned that
interleukin-7 (IL-7), a pro-lymphoid growth and survival factor
involved in the development, maintenance, and proliferation of
T cells, would promote CAR T cell efﬁcacy and tumor cell killing
in vivo.
rhIL-7-hyFc (eﬁneptakin alfa, NT-I7) is a homodimeric
genetically modiﬁed IL-7 molecule fused to a stable hyFc
platform7, which prevents complement activation while
prolonging in vivo serum half-life, providing clear pharmacologic
advantages to short-lived native recombinant human IL-7 (rhIL7). In the ﬁrst human trial with healthy volunteers
(NCT02860715), a single-dose intramuscular injection of rhIL-7hyFc (60 mcg/kg) resulted in a substantial increase in the number
of CD4+ and CD8+ T cells, and no major adverse events or
dose-limiting toxicities were reported8. Therefore, we decided to
explore the potential of this reagent to augment the activity of
CAR T cells.
Here we show that rhIL-7-hyFc dramatically enhances CAR T
cell expansion, persistence, and anti-tumor efﬁcacy, resulting in
signiﬁcantly prolonged survival of mice in CD19+ lymphoma and
CD33+ leukemia xenograft models treated with human CAR
T cells, and in immunocompetent mice bearing CD19+ tumors
treated with murine CAR T cells. Immunocompetent mice that
received rhIL-7-hyFc with CAR T cells exhibited sustained B cell
aplasia and were protected against tumor rechallenge. Functional
studies and single-cell RNA-seq (scRNA-seq) reveal that rhIL-7hyFc not only increases CAR T cell numbers but also improves T
cell cytotoxicity and decreases exhaustion. Therefore, rhIL-7-hyFc
has the potential to improve the outcomes of CAR T cell treatment in patients with refractory malignancies.
Results
rhIL-7-hyFc enhances the expansion of UCART19 in vitro and
maintains CAR-T polyfunctionality. To test the effects of rhIL7-hyFc (Fig. 1a) on CAR T cells in vitro, human TCR-deﬁcient
anti-CD19 CAR T cells (UCART19) were cultured with rhIL-7hyFc in the presence of CD19+ tumor cells. We used TCR
deleted human CAR T cells to eliminate the potential for xenogeneic graft versus host disease (GVHD) confounding future
in vivo experiments. UCART19 was generated from human
T cells derived from healthy donors activated with anti-CD3/antiCD28 beads for two days before electroporation with Cas9
mRNA and a TRAC-targeted gRNA. T cells were then transduced
with a lentivirus expressing a 3rd generation anti-CD19 CAR (1928-BBζ) containing a 2A-cleaved human CD34 extracellular
domain, permitting ex vivo puriﬁcation and identiﬁcation of CAR
+ cells (Fig. 1b). CRISPR/Cas9-mediated TRAC deletion efﬁciency was more than 97%, with an average 58% CAR transduction efﬁciency (Supplemental Fig. 1). Ramos, a CD19+
B-lymphoma cell line, transduced with click beetle red luciferase
(CBR) and green ﬂuorescent protein (GFP; hereafter, RamosCBRGFP), was co-cultured with UCART19 at an effector to target
(E:T) ratio of 2:1 in either vehicle control, rhIL-7 10 ng/ml, or
rhIL-7-hyFc (10, 100 or 1000 ng/ml). Seven days later, UCART19
was replated in fresh media containing rhIL-7 or rhIL-7-hyFc,
and re-challenged with RamosCBR-GFP (Fig. 1c). Vehicle only
controls failed to expand over the 14-day assay period, while
2

supplementation with either rhIL-7 or rhIL-7-hyFc at concentrations in excess of 10 ng/ml led to robust expansion of
UCART19 (Fig. 1d). Qualitative assessment of UCART19 on day
14 post co-culture with rhIL-7 or rhIL-7-hyFc revealed that even
at the lowest concentration, rhIL-7-hyFc promoted UCART19
viability, prevented apoptosis, and increased proliferation to the
same degree as rhIL-7 (Fig. 1e).
To further characterize rhIL-7-hyFc expanded UCART19 cells,
single-cell cytokine analyses using the Isoplexis Isolite platform
were performed on UCART19 isolated and puriﬁed from vehicle
and rhIL-7-hyFc (100 ng/ml) treated samples on day 14 and
compared to UCART19 from day 0, prior to tumor challenge.
The Isolite Isocode assay enables the detection and quantiﬁcation
of 32 secreted cytokines from individual CAR T cells to deﬁne
polyfunctional strength index (PSI), a quantitative marker of
CAR-T functionality9. Despite the robust rhIL-7-hyFc-mediated
UCART19 expansion, no loss of functionality was associated with
rhIL-7-hyFc treatment as deﬁned by PSI, with the rhIL-7-hyFc
expanded UCART19 maintaining a similar PSI to UCART19
input cells from the start of the experiment on day 0 (Fig. 1f and
Supplemental Fig. 2A, B). Polyfunctionality was driven by the
secretion of effector molecules such as granzyme B, IFNγ, MIP1α, MIP-1β, perforin, TNF-α, and TNF-β (Supplemental Fig. 2C).
Flow cytometry-based immunophenotyping revealed that
samples treated with rhIL-7-hyFc preferentially maintained the
percentage of CAR+ cells, while a signiﬁcant loss of CARexpressing cells was noted over the duration of the assay in
samples treated with vehicle (Fig. 1g). Additionally, rhIL-7-hyFc
also increased the proportion of central memory T cells of
UCART19 after serial in vitro tumor challenge as compared to
vehicle-treated cells (Fig. 1h). Overall, these data indicate that
rhIL-7-hyFc potentiates the expansion of functional UCART19
cells in vitro.
rhIL-7-hyFc enhances UCART19 expansion, persistence, and
anti-tumor efﬁcacy in vivo resulting in prolonged survival of
CD19+ tumor-bearing NSG mice. We predicted rhIL-7-hyFc
would enhance in vivo expansion of UCART19 and improve antitumor efﬁcacy. To test this hypothesis, we used a preclinical
mouse model where UCART19 treatment of tumor-bearing NSG
mice leads to only a modest increase in survival. NSG mice were
injected with 5 × 105 RamosCBR-GFP four days before treatment
with 1 × 106 UCART19 cells, followed by 10 mg/kg of rhIL-7hyFc subcutaneously on days +1, +15, and +29 after UCART19
infusion (Fig. 2a). Of note, lymphoid tumor cell lines (Ramos,
HH, Jurkat, and CCRF-CEM) express the IL-7 receptor (CD127),
albeit at levels lower than activated normal T cells (Supplemental
Fig. 3), raising the possibility that a preponderant effect of rhIL-7hyFc on tumor growth would outweigh any beneﬁcial effect of
rhIL-7-hyFc on UCART19 activity and tumor killing. However,
survival of NSG mice bearing RamosCBR-GFP after rhIL-7-hyFc
treatment was equivalent to mice receiving RamosCBR-GFP cells
alone (Fig. 2b), indicating no overtly deleterious pro-lymphoma
effects of rhIL-7-hyFc in this model. As expected, RamosCBR-GFP
bearing NSG mice had only a modest survival beneﬁt after
UCART19 treatment alone in this aggressive B lymphoma model
compared to untreated mice. Remarkably, 100% of RamosCBRGFP bearing mice treated with UCART19 and rhIL-7-hyFc were
alive beyond 80 days, with no clinical signs of xenogeneic GVHD.
Bioluminescent imaging (BLI) revealed minimal tumor signal in
UCART19 + rhIL-7-hyFc-treated mice over long-term follow-up
(Fig. 2c, d). Additionally, quantitative ﬂow cytometric analyses of
peripheral blood revealed a four log-fold expansion of UCART19
in rhIL-7-hyFc-treated mice compared to vehicle-treated mice
(Fig. 2e, f and Supplemental Fig. 4). Contrary to our in vitro
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results, the UCART19 cells expanded in vivo with rhIL-7-hyFc
demonstrated a more pronounced effector memory phenotype
compared to the input T cells (Supplemental Fig. 5).
rhIL-7-hyFc enhances expansion, persistence, and anti-tumor
efﬁcacy of UCART33 resulting in prolonged survival of
CD33+ tumor-bearing NSG mice. To conﬁrm that the effects of
rhIL-7-hyFc on CAR T cells were not limited to UCART19 only,
we tested rhIL-7-hyFc in a similar way using an orthogonal
myeloid-targeting CAR T in an NSG model of acute myeloid
leukemia. UCART33 is a second-generation CAR with a 4-1BB,
CD3ζ endodomain and an extracellular scFv targeting human

ARTICLE

CD33. CAR T cells were generated as previously described for
UCART19, with gene editing of TRAC to allow for long-term
follow-up of NSG mice without xenogeneic GvHD. NSG mice
were injected with 5 × 104 U937CBR-GFP four days prior to the
administration of 1 × 106 UCART33 cells, followed by rhIL-7hyFc 10 mg/kg subcutaneously on days +1, +15, and +29
(Fig. 3a). While UCART33 therapy alone only moderately prolonged median survival in the absence of rhIL-7-hyFc, all mice
receiving UCART33 in combination with rhIL-7-hyFc remained
alive until the end of the experiment at 175 days post-UCART33
infusion (Fig. 3b). No tumor was detectable in any of the rhIL-7hyFc treated U937CBR-GFP bearing NSG mice after 35 days until
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Fig. 1 rhIL-7-hyFc enhances UCART19 expansion and function in vitro. a rhIL-7-hyFc is an engineered IL-7 homodimer fused to IgD and IgG4 elements
(hyFc©), promoting in vivo stability and reducing complement activation. b UCART19 was generated by activating human T cells with anti-CD3/CD28
beads, followed by CRISPR/Cas9 deletion of the human T cell receptor alpha subunit (TRAC), and lentiviral transduction of a third-generation anti-CD19
CAR. c–e UCART19 was incubated with CD19+ RamosCBR-GFP at an effector to target (E:T) ratio of 2:1 in 10 ng/ml of rhIL-7 or the indicated concentrations
of rhIL-7-hyFc. On day 7, UCART19 was replated with RamosCBR-GFP at an E:T of 2:1 with the addition of fresh cytokines. UCART19 numbers and
phenotypes were determined by serial counting and ﬂow cytometry. Bar graphs represent median values, with each data point representing a different T
cell donor. d Representative growth plot for a single donor (left) and compiled fold-expansion of all donors on day 14 (right, n = 3 donors for rhIL-7, 4
donors for all other groups). p Values were calculated by one-way ANOVA with Tukey’s multiple comparisons test (rhIL-7 10 vs. 0, p = 0.0055, rhIL-7hyFc 10 vs. 0, p = 0.0246, rhIL-7 10 vs. rhIL-7-hyFc, p = 0.82). e UCART19 viability (%propidium iodide exclusion, rhIL-7 10 vs. 0: p < 0.0001; rhIL-7-hyFc
10 vs. 0: p < 0.0001; rhIL-7 10 vs. rhIL-7-hyFc: p = 0.9999), apoptosis (%annexinV+, rhIL-7 10 vs. 0: p = 0.0005; rhIL-7-hyFc 10 vs. 0: p = 0.0002; rhIL-7
10 vs. rhIL-7-hyFc: p = 0.9615) and proliferation (%Ki-67+, rhIL-7 10 vs. 0: p < 0.0001; rhIL-7-hyFc 10 vs. 0: p < 0.0001; rhIL-7 10 vs. rhIL-7-hyFc:
p = 0.9805) measured after rhIL-7 or rhIL-7-hyFc treatment in the presence of target cells after 14 days (n = 3 different donors). P-values were calculated
by one-way ANOVA with Tukey’s multiple comparisons test. f UCART19 was incubated with Ramos at an E:T of 1:1 for 16 h with either vehicle or rhIL-7yhyFc (100 ng/ml) prior to loading puriﬁed CAR T cells onto the IsoCode chip for single-cell multiplex cytokine analysis. Polyfunctional strength index (PSI),
as deﬁned by the percentage of cells secreting multiple cytokines multiplied by the mean ﬂuorescence intensity of the secreted proteins, was calculated for
UCART19 on day 0 (UCART19 input cells), day 14 with vehicle, or day 14 with rhIL-7-hyFc. Bar graphs represent mean ± standard error of the mean (n = 1
donor, 2 technical replicates for day 0, 3 technical replicates for day 14 vehicle/rhIL-7-hyFc). Further details regarding the cytokines assayed,
polyfunctionality, and signal strength is depicted in Supplemental Fig. 2. g, h UCART19 cells serially expanded in the presence of rhIL-7-hyFc and CD19+
Ramos cells at a 2:1 E:T ratio as in c were evaluated by ﬂow cytometry on day +14. Bar graphs represent mean ± SD of four technical replicates (n = 1
donor). g CAR expression analysis on day +14 in CD4+ and CD8+ T cells (left), with representative ﬂow cytometry plots of UCART19 using CD34 to
deﬁne CAR-T populations (right). h Memory phenotype of T cells as measured by expression of CCR7 and CD45RO (T-EFF effector T cells, T-EM effector
memory T cells, T-CM central memory T cells, T-N naive T cells). Source data are provided as a Source data ﬁle. ns: not signiﬁcant, *p ≤ 0.05, **p ≤ 0.01,
***p ≤ 0.001, ****p ≤ 0.0001.

the end of the experiment (Fig. 3c, d). A logarithmic expansion of
UCART33 was seen only in mice that also received rhIL-7-hyFc
(Fig. 3e). Of note, UCART33 expansion was not observed with
rhIL-7-hyFc in a cohort of mice that did not have prior tumor
engrafted, indicating that antigen recognition is also required for
rhIL-7-hyFc driven CAR T cell expansion. The dramatic
enhancement of UCART33 expansion, persistence, and antitumor efﬁcacy against CD33+ AML targets in vivo by rhIL-7hyFc recapitulate our data generated using UCART19, suggesting
that rhIL-7-hyFc potentiation of UCART expansion and clinical
efﬁcacy is likely applicable to multiple other CAR T platforms
and targets.
rhIL-7-hyFc can improve CAR T cell expansion and persistence
in immunocompetent mice. The dramatic expansion of CAR
T cells in NSG mice with rhIL-7-hyFc treatment prompted
concern that rhIL-7-hyFc may exacerbate the toxicities of CAR T
cell therapy in human subjects. Alternatively, while rhIL-7-hyFc
can support CAR T cell expansion in NSG mice that lack
endogenous lymphoid cells, in an immunocompetent host it
would also stimulate the endogenous immune system, which may
potentially lead to rejection of CAR T cells. To address these
concerns, we transitioned to an immunocompetent mouse model,
to better evaluate the effects of rhIL-7-hyFc on CAR T cells in the
setting of a functional host immune system, and to assess whether
this may compromise the health of the host. C57BL/6 mice were
injected with syngeneic leukemia cells expressing CD19, followed
by treatment with untransduced (UTD) control T cells or murine
CD19-targeting CAR T cells (mCART19), then given rhIL-7-hyFc
(Fig. 4a). In this experiment, we used high doses of mCART19
(6 × 106 cells/mouse) to ensure that any potential toxicity of this
therapy would manifest. Tumor cells were derived from a murine
acute promyelocytic leukemia cell line, 9523, previously generated
in our lab, to which murine CD19 expression was added by
lentiviral gene transfer. Adoptively transferred T cells were
derived from CD45.1+ donor splenocytes, to facilitate
tracking of the cells in CD45.2+ recipient mice, and transduced
with a murine CD19-targeting CAR construct that also contained
GFP for better tracking of CAR+ cells. UTD cells were
expanded simultaneously with mCART19 but not transduced
4

with the CAR. Prior to T cell infusion mice were given cyclophosphamide (Cytoxan) for lymphodepletion, as this has been
shown to be important for the activity of adoptively transferred
cells10.
mCART19 alone at this dose was highly effective, and the
majority of mice survived long-term, regardless of rhIL-7-hyFc
administration (Fig. 4b). Importantly, no toxicity was observed in
any of the mice that received mCART19 and rhIL-7-hyFc. Mice
did not lose weight or exhibit any clinical signs of distress, and
hemoglobin and platelet levels remained for the most part within
the normal range (Supplemental Fig. 6a, b). Plasma IL-6 levels
were mildly elevated at day +5 after T cell infusion (Supplemental
Fig. 6c) and subsequently became undetectable at day +10 for all
groups (data not shown). In these mice that had a fully functional
immune system, total white blood cell (WBC) counts increased in
all mice that received rhIL-7-hyFc, but the degree of elevation did
not reach the supra-physiological levels seen in NSG mice
(Fig. 4c). Numbers of peripheral blood mCART19, as assessed by
ﬂow cytometry for GFP+ cells, increased by approximately 4-fold
with rhIL-7-hyFc as compared to mCART19 alone (Fig. 4d and
Supplemental Fig. 7). Additionally, in mice that received rhIL-7hyFc, mCART19 was detected beyond 6 weeks, in contrast to
mice receiving mCART19 alone, where minimal CAR T cells
were detected after 3 weeks. These ﬁndings conﬁrm that rhIL-7hyFc prolongs CAR T cell expansion and persistence even in an
immunocompetent host, without undue toxicity.
Flow cytometry analysis also revealed that the leukocytosis seen
after rhIL-7-hyFc treatment was predominantly of recipient
origin (CD45.2+), and adoptively transferred CD45.1+ cells
comprised only 10-20% of total WBCs across all timepoints
(Fig. 4e). Control mice had an increase of both recipient B and
T cells with rhIL-7-hyFc, while in mCART19-treated mice
recipient T cells were the main drivers of leukocytosis, due to
the expected loss of B cells after this treatment (Fig. 4e, f).
Notably, recipient T cells outnumbered mCART19 by approximately 10-fold with rhIL-7-hyFc treatment (day +24, median
recipient T cells: 11,359 cells/μl, median mCART19: 964 cells/μl),
but we did not see a rejection of the CAR T cells, and B cell
aplasia in the mice was sustained throughout the duration of this
experiment.
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Fig. 2 rhIL-7-hyFc dramatically enhances UCART19 expansion, persistence, and anti-tumor efﬁcacy in NSG mice engrafted with CD19+ RamosCBR-GFP
cells in vivo. a Experimental schema: NSG mice were injected via tail vein with 5 × 105 Ramos B lymphoma cells expressing click beetle red luciferase
(CBR) and green ﬂuorescent protein (GFP) (RamosCBR-GFP) on day −4, followed by 1 × 106 UCART19 on day 0, and rhIL-7-hyFc 10 mg/kg subcutaneously
every 2 weeks for a total of three doses starting day +1 (n = 5 for no tx and rhIL-7-hyFc only groups; n = 10 for UCART19 and UCART19 + rhIL-7-hyFc
groups). b Survival analysis for each treatment group. p Values were calculated using two-sided Wilcoxon test (UCART19 + rhIL-7-hyFc vs. UCART19
alone, p = 0.018). c Tumor burden measured by bioluminescent imaging (BLI). Data represent median ± 95% CI. Two-tailed p values were calculated using
linear mixed model for repeated measurement data followed by post hoc multiple comparisons for between-group differences (UCART19 + rhIL-7-hyFc vs.
UCART19 alone, p < 0.0001). d BLI images of individual mice treated with UCART19 only (left) and UCART19 + rhIL-7-hyFc (right). e, f Quantitative ﬂow
cytometric analyses of UCART19 expansion in peripheral blood. Representative FACS plots (e) and absolute UCART19/μl counts from peripheral blood (f).
Each data point represents one mouse. Two-tailed p-values were calculated using a linear mixed model for repeated measurement data followed by post
hoc multiple comparisons for between-group differences (UCART19 + rhIL-7-hyFc vs. UCART19 alone, p < 0.0001). Source data are provided as a Source
data ﬁle. *p ≤ 0.05, ****p ≤ 0.0001.

rhIL-7-hyFc improves survival of CD19+ tumor-bearing Balb/
c mice after mCART19. To conﬁrm that rhIL-7-hyFc enhances
CAR T cell anti-tumor activity in an immunocompetent host, we
transitioned to using a B cell lymphoma cell line, A20, that
expresses murine CD19, engrafted into Balb/c mice. To enable
tracking of the tumor by BLI we used A20 cells transduced with
CBR-GFP, which requires sublethal irradiation of the mice prior
to prevent rejection of the tumor by endogenous immune cells.
Mice received A20CBR-GFP cells either 5 × 105 intravenously (IV)
or 1 × 106 subcutaneously (SC), and 7 days later were given
5 × 105 mCART19 cells without further conditioning, followed by
rhIL-7-hyFc 10 mg/kg on days +1 and +15 (Fig. 5a). Due to
prolonged thrombocytopenia in the mice after irradiation we
were unable to evaluate peripheral blood CAR T cell expansion at

early time points; however, we did conﬁrm on day +57 that mice
that had received rhIL-7-hyFc had higher numbers of circulating
CAR T cells as compared to mCART19 alone (Fig. 5b). In both
the IV and SC tumor models, the tumor was better controlled
with rhIL-7-hyFc, which led to improved survival in mice that
received rhIL-7-hyFc after mCART19 treatment (Fig. 5c, d).
Additional evaluation of T cell phenotype on day +57 by ﬂow
cytometry revealed that in contrast to the endogenous T cells,
which were predominantly naive T cells, mCART19 cells were
mostly comprised of memory T cells (Fig. 5e and Supplemental
Figs. 8 and 9). The addition of rhIL-7-hyFc did not signiﬁcantly
change the proportion of T cell subsets for the most part,
although there was a slight increase in effector CAR T cells and a
decrease in central memory CAR T cells. In general, we observed
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Fig. 3 rhIL-7-hyFc enhances UCART33 expansion, persistence and anti-tumor efﬁcacy in NSG mice engrafted with CD33+ U937CBR-GFP cells in vivo.
a UCART33 are human T cells gene-edited to delete TRAC and then transduced with a lentivirus carrying a second-generation CAR construct targeting
CD33 with a 4-1BB endodomain. NSG mice were injected with 5 × 104 U937CBR-GFP four days prior to administration of either 1 × 106 UTD (untransduced
T cells) or UCART33 cells, followed by rhIL-7-hyFc 10 mg/kg subcutaneously on days +1, +15, and +29 (n = 5/group for UTD, UTD + rhIL-7-hyFc,
UCART33, n = 10 for UCART33 + rhIL-7-hyFc). b Survival analysis for each treatment group. p Values were calculated using two-sided Wilcoxon test.
(UCART33 + rhIL-7-hyFc vs. UCART33 alone, p = 0.0015). c, d Serial tumor measurements by BLI. Data represent median ± 95% CI. Two-tailed p values
were calculated using a linear mixed model for repeated measurement data followed by post hoc multiple comparisons for between-group differences
(UCART33 + rhIL-7-hyFc vs. UCART33 alone, p < 0.0001). e Quantitative ﬂow cytometric analyses of UCART33 expansion in peripheral blood; also shown
is a subgroup of mice (n = 5) that received UCART33 and rhIL-7-hyFc without prior tumor injection. Two-tailed p values were calculated using a linear
mixed model for repeated measurement data followed by post hoc multiple comparisons for between-group differences (UCART33 + rhIL-7-hyFc vs.
UCART33 alone, p = 0.0053). Source data are provided as a Source data ﬁle. **p ≤ 0.01, ****p ≤ 0.0001.

better expansion of CAR T cells as compared to endogenous
T cells at this later time point, with the largest fold-change seen in
the CD4+ effector and effector memory CAR T cells after rhIL-7hyFc (Fig. 5f). These ﬁndings corroborate our ﬁndings in human
CAR T cells, in that rhIL-7-hyFc leads to increased CAR T cell
numbers, and this is more prominent within the effector and
effector memory cell populations.
Long-term surviving mice after mCART19 or mCART19+rhIL-7-hyFc were protected from rechallenge with IV A20 tumor
cells on day +100, regardless of whether the initial tumor was
given IV or SC (Fig. 5g). Notably, on day +28 post-rechallenge
(day +128 from initial T cell infusion), mice that had been
previously treated with mCART19+rhIL-7-hyFc continued to
have signiﬁcantly higher numbers of CAR T cells detected in the
peripheral blood than mice that had received mCART19 alone
(Fig. 5h).
rhIL-7-hyFc reduces the minimum effective dose of CART19.
Given the pronounced effect of rhIL-7-hyFc on CAR T cell
expansion and efﬁcacy, we hypothesized that rhIL-7-hyFc could
reduce the minimum effective dose of CAR T cells required for
6

activity. To test this, we injected Balb/c mice with A20 tumor
cells, followed by Cytoxan conditioning, and 5 × 104, 2.5 × 105, or
1.25 × 106 mCART19 cells, with or without rhIL-7-hyFc treatment (Fig. 6a). Due to the anti-tumor effects of the Cytoxan
conditioning, the majority of the mice survived long-term in this
experiment (Fig. 6b).
The addition of rhIL-7-hyFc increased the numbers of CAR
T cells across all dose levels (Fig. 6c). Using the highest dose of
1.25 × 106 mCART19 cells as a benchmark, we found that rhIL-7hyFc increased both the peak expansion and persistence of the
next dose level of 2.5 × 105 cells beyond that seen with a ﬁve-fold
higher dose of mCART19 alone. However, at the lowest dose of
5 × 104 mCART19 cells, the addition of rhIL-7-hyFc only
transiently increased peak levels of mCART19. Using circulating
B cells as a biomarker of CAR T cell activity, we found that
without rhIL-7-hyFc, mice treated with 2.5 × 105 mCART19
recovered B cells after 3 weeks, while the addition of rhIL-7-hyFc
led to prolonged B cell aplasia. Notably, control mice had a
massive increase in B cell numbers after rhIL-7-hyFc, but mice
treated with 2.5 × 105 or more mCART19 with rhIL-7-hyFc were
still able to completely eliminate all detectable circulating B cells.
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Fig. 4 rhIL-7-hyFc enhances mCART19 expansion and persistence in immunocompetent mice. a C57BL/6J mice were injected with 5 × 104 syngeneic
tumor cells (9523, a myeloid cell line to which murine CD19 expression was added) followed by cyclophosphamide (Cytoxan) conditioning one day prior to
receiving 6 × 106 UTD or murine CART19 (mCART19), then given serial injections of rhIL-7-hyFc on days +1, +15, and +29 (n = 4/group). b Overall
survival of mice in each group. p Values were calculated using two-sided Wilcoxon test (mCART19 + rhIL-7-hyFc vs. mCART19, p = 0.32, mCART19+rhIL7-hyFc vs. UTD + rhIL-7-hyFc, p = 0.044). c Peripheral blood total WBC counts over time. d Absolute numbers of mCART19 cells over time. e Total WBC
counts were fractionated by ﬂow cytometry into percent CD45.1+ (adoptively transferred T cells) and CD45.2+ (endogenous cells); CD45.2 cells are
subdivided into CD19+ B cells, CD3+ T cells, and Gr-1+ myeloid cells at the indicated timepoints. f Absolute numbers of CD45.2+ B cells, T cells, and
myeloid cells over time, calculated by multiplying the total WBC count by the fraction of each cell determined by ﬂow cytometry. All data represent
median ± range. Dotted lines represent rhIL-7-hyFc injection time points. Source data are provided as a Source data ﬁle. ns: not signiﬁcant, *p ≤ 0.05.

Also, while the 5 × 104 mCART19 + rhIL-7-hyFc-treated mice
were not able to clear B cells at any time point, these mice did not
exhibit the marked increase in B cell numbers seen in the control
group, suggesting that even this low cell dose had some effect
against target cells when augmented by rhIL-7-hyFc (Fig. 6d). B
cell aplasia was sustained beyond 100 days in mice receiving
2.5 × 105 mCART19 or higher with rhIL-7-hyFc, while mice that
received any dose of mCART19 alone had B cell recovery
(Fig. 6e). These results indicate that while a minimum dose of
mCART19 is still required to achieve beneﬁt from rhIL-7-hyFc,
adding this reagent can lower the effective dose of mCART19 by
at least ﬁvefold, and enhance the durability of this treatment.
To ensure that these dose-sparing effects of rhIL-7-hyFc were
also applied to human CAR T cells, we injected RamosCBR-GFP
engrafted NSG mice with limiting doses of UCART19 starting at
5 × 104 cells followed by rhIL-7-hyFc treatment. Similar to the

murine CAR T cell studies, the 5 × 104 dose UCART19 did not
have any effect on the tumor even with the addition of rhIL-7hyFc. However, 2.5 × 105 UCART19 cells combined with rhIL-7hyFc achieved tumor control in 3/5 mice, in contrast to mice
given 2.5 × 105 UCART19 alone, where all mice had rapid tumor
progression and died. As expected, the highest dose of 1.25 × 106
UCART19 in combination with rhIL-7-hyFc mediated tumor
regression in all mice (Fig. 6f). Again, the degree of tumor control
and survival seen with 2.5 × 105 UCART19 combined with rhIL7-hyFc surpassed that seen with ﬁvefold higher doses of
UCART19 alone, indicating that rhIL-7-hyFc may allow for
treatment with much lower CAR T cells doses than conventionally used, and still lead to better outcomes.
In vivo treatment with rhIL-7-hyFc enhances both the quantity
and quality of CAR T cells. To determine whether the effects of
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rhIL-7-hyFc were mediated solely by the quantitative increase
in CAR T cell numbers, or whether there were also differences
in the functionality CAR T cells, we harvested CAR T cells from
mice after in vivo rhIL-7-hyFc treatment and reassessed their
properties in vitro. Balb/c mice were given Cytoxan conditioning 1 day prior to receiving 2 × 106 UTD or mCART19
cells and injected with a single dose of rhIL-7-hyFc 10 mg/kg on
day +1. Spleens were harvested from mice at 7 and 14 days
after T cells. Spleen size and cell numbers were increased in
both control and mCART-treated mice after rhIL-7-hyFc
(Fig. 7a). Fractionation of cells within the spleen again
revealed that expansion of the endogenous lymphoid
8

compartment drives the majority of responses to rhIL-7-hyFc
in immunocompetent mice (Fig. 7b). Absolute numbers of
mCART19 cells in the spleen were higher after rhIL-7-hyFc
treatment, with average cell numbers increasing from day +7 to
day +14, in contrast to vehicle-treated mice where mCART19
numbers decreased during this time (Fig. 7c). As expected,
rhIL-7-hyFc decreased apoptosis (Fig. 7d) and increased proliferation (Fig. 7e) of the adoptively transferred T cells. Evaluation of cytotoxicity (Fig. 7f) and intracellular cytokine
production (Fig. 7g) of puriﬁed mCART19 cells against A20
tumor cells revealed enhanced effector functions after exposure
to rhIL-7-hyFc.
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Fig. 5 rhIL-7-hyFc improves the anti-tumor efﬁcacy of mCART19 in immunocompetent mice. a Balb/c mice were given sublethal irradiation (600 cGy),
followed by injection with a syngeneic B cell lymphoma cell line, A20CBR-GFP, either 5 × 105 cells intravenously (IV) or 1 × 106 cells subcutaneously (SC),
then given 5 × 105 mCART19 cells and serial injections of rhIL-7-hyFc on days +1 and +15 (n = 4–5/group). b Absolute numbers of peripheral blood CAR
T cells in each group measured at day +57. Lines represent median values, with each data point representing one mouse (IV A20 + CART + rhIL-7-hyFc
vs. CART only, p = 0.017, SC A20 + CART + rhIL-7-hyFc vs. CART only, p = 0.002). c For mice given A20 IV, BLI measurements of tumor burden (left,
each line represents one mouse), and overall survival (mCART19 vs. mCART19+rhIL-7-hyFc, p = 0.13, mCART19 vs. rhIL-7-hyFc only, p = 0.04). d For
mice given A20 SC, BLI measurements of tumor burden (left, each line represents one mouse), and overall survival (mCART19 vs. mCART19+rhIL-7-hyFc,
p = 0.016, mCART19 vs. no treatment, p = 0.018). e, f Day +57 peripheral blood ﬂow cytometry evaluation of naive (T-N), central memory (T-CM),
effector memory (T-EM), and effector (T-EFF) T cell populations within endogenous and CAR T cells with and without rhIL-7-hyFc, subdivided by CD4+
and CD8+ T cells. For this analysis, values from mice that received IV and SC tumor were pooled for each group (no rhIL-7-hyFc: n = 6, +rhIL-7-hyFc:
n = 10). T cell memory subsets were deﬁned using expression of CD62L and CD44 as indicated in f. e Proportions of T-N, T-CM, T-EM, and T-EFF within
the CD4+ and CD8+ T cells in endogenous T cells and mCART19. Bar graphs represent median values, with each data point representing one mouse. p
Values are provided in the Source data ﬁle. f Fold-change of T cell subsets were calculated by averaging the absolute numbers of each cell subset, and
dividing the numbers for mCART19+rhIL-7-hyFc treated mice over mCART19 only controls. CART4 = CD4+ CAR T cells, CART8 = CD8+ CAR T cells,
4 = endogenous CD4+ T cells, 8 = endogenous CD8+ T cells. g Long-term surviving mice were rechallenged with 1 × 106 A20 cells (without CBR-GFP) IV
on day +100. A separate cohort of mice with no prior treatment was also injected with A20 tumor cells on the same day as controls (n = 4). h Peripheral
blood CAR T cell numbers at day +28 post-rechallenge. mCART19+rhIL-7-hyFc (n = 9) vs. mCART19 (n = 3), p = 0.014. p values for survival curves were
calculated using two-sided log-rank test, and for b, e, h by two-sided unpaired Student’s t test. Source data are provided as a Source data ﬁle. No tx: no
treatment, ns: not signiﬁcant, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.

We also evaluated the cytotoxicity of UCART19 cells extracted
from the spleens of NSG mice treated with rhIL-7-hyFc. Mice that
received rhIL-7-hyFc had markedly enlarged spleens as compared
to control mice (Fig. 7h), with UCART19 comprising >90% of
splenocytes (data not shown). As spleens from control mice had
insufﬁcient UCART19 cells to assay, the efﬁcacy of UCART19
killing after in vivo rhIL-7-hyFc treatment was compared to
cryopreserved cells from the same batch of UCART19 infused
into the mice on day 0 (input). In vivo rhIL-7-hyFc treated
UCART19 displayed signiﬁcantly greater cytotoxicity than input
UCART19 against CD19+ Ramos and Nalm6 tumor cell lines
(Fig. 7i, j), with input controls requiring 2–4-fold greater numbers
of effector cells to achieve equivalent cytotoxicity to UCART19
from rhIL-7-hyFc treated mice. These results indicate that rhIL-7hyFc not only increases CAR T cell numbers but also enhances
the effector functions of CAR T cells against the tumor.
Single-cell RNA sequencing (scRNA-seq) demonstrates that
rhIL-7-hyFc preferentially expands IL7R+ effector memory
CAR T cells. To further elucidate the effects of rhIL-7-hyFc on
CAR T cell phenotype, scRNA-seq was performed on UCART19
derived from spleens of rhIL-7-hyFc treated NSG mice (Fig. 8a).
Due to low cell numbers and poor viability, we were unable to
analyze UCART19 cells collected from Ramos engrafted NSG
mice given UCART19 alone, so cryopreserved cells from the same
batch of UCART19 infused into the mice on day 0 were used as
the comparator group to rhIL-7-hyFc treated UCART19. After
stringent ﬁltering, a total of 27,676 cells were identiﬁed, with 2489
cells derived from day +14 (week 2), 16,367 cells from day +28
(week 4), and 7911 cells from the UCART19 input cells (Input).
The integration of all cells using Seurat identiﬁed a total of 15
unique T cell clusters, with varying proportions of cells mapped
back to each treatment time point (Fig. 8b, c). While most T cell
clusters were maintained across treatment timepoints, clusters 0
and 1 showed a dramatic increase at week 4. Downsampled
UMAP projections (n = 2000 cells) further highlight the predominance of clusters 0 and 1 at week 4, relative to input and
week 2 (Fig. 8d).
Previous studies have established the alternative splicing
repertoire of naive and memory T cells involving exons 4, 5,
and 6 of PTPRC, where isoforms RBC and RAB are speciﬁc to
naive T cells, the RB isoform is shared by naive and memory
T cells, and RO is speciﬁc to memory T cells11,12. To evaluate the
T cell representation within our samples, we quantiﬁed the

isoform expression of PTPRC (CD45), by utilizing sjcount
(https://github.com/pervouchine/sjcount) to quantify splice junction counts across the scRNA-seq dataset (Supplemental Fig. 10).
By comparing the proportion of overall reads that spanned exon 3
and downstream exons 4, 5, or 7, the majority of reads could be
identiﬁed as either RO or RB/RBC. To evaluate whether the
predominant isoform was RB or RBC, we then quantiﬁed the
total reads mapped from exon 5 to downstream exons 6 or 7, and
found a majority of reads supported the RB isoform. Therefore,
isoform analysis of PTPRC provides additional evidence that the
vast majority of UCART19 after rhIL-7-hyFc treatment are
memory T cells.
We then mapped the PTPRC isoforms back to the T cell
clusters identiﬁed by Seurat, and found that cluster 4 had a high
fraction of the RBC isoform speciﬁc to naive T cells. After
determining the likely naive T cell group, we then performed
trajectory analysis using Monocle3 to evaluate the developmental
transitions between T cell clusters. A UMAP of all T cell clusters
and the overlapping trajectory indicates that cells starting with
cluster 4 (naive T cells) transition to several downstream clusters,
including cluster 1 and cluster 0, which harbor more of an
effector memory state, before transitioning to a number of
additional T cell states (Fig. 8c).
To further characterize the different T cell clusters, we
annotated each cluster by the expression of well-known T cell
markers: CD4, CD8A, CCR7, and SELL13. Most of the CD8
clusters had an effector memory phenotype (clusters 1,2,3,8;
CD8A+/CCR7−/SELL−), while one cluster had a naive/central
memory phenotype (cluster 4; CD8A+/CCR7+/SELL−), and one
was intermediate (cluster 10; CD8A+/CCR7−/SELL+). Cluster
10 also had high expression of CD27 and PTPRC isoform RB
(CD45RB), which has been reported in long-lived memory T cell
groups11. Similarly, for the CD4 clusters, the majority of cells
were effector memory (clusters 0,6,9; CD4+/CCR7−/SELL−),
while one cluster was distinctly central memory (cluster 7; CD4+/
CCR7+/SELL+). All of the remaining populations (clusters 5, 11,
12, 13, 14) lacked expression of CCR7 and SELL (Fig. 8f).
We also calculated the exhaustion scores14–16 of the T cells
using a Seurat scoring function based on the expression of the
following well-known exhaustion markers: CTLA4, PDCD1,
LAG3, HAVCR2, CD160, CD244, and TIGIT. The overall
exhaustion score was strikingly higher in the input sample and
decreased with successive treatment timepoints, leaving only a
subset of cells in cluster 10 at week 4 containing an exhaustive T
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Fig. 6 rhIL-7-hyFc reduces the number of CAR T cells required for the biological effect. a–e Balb/c mice were ﬁrst given 1 × 106 A20 tumor cells,
followed by cyclophosphamide (Cytoxan) conditioning 1 day prior to receiving mCART19 (5 × 104, 2.5 × 105, or 1.25 × 106 cells per mouse), then given
serial injections of rhIL-7-hyFc on days +1, +15, and +29 (n = 4/group). b Overall survival of mice for all groups. c Peripheral blood CAR T cell
expansion was measured over time by quantiﬁcation of CD45.1+GFP+ cells. Each line represents values from one mouse. d B cell numbers were
measured over time by quantiﬁcation CD45.2+ CD19+ cells. Data represented as median ± range. Note that 5 × 104 cells (left panel) are depicted on a
different scale. e B cell numbers on day +101 after T cell injection. f NSG mice were injected with 5 × 105 RamosCBR-GFP followed by UCART19
treatment (5 × 104, 2.5 × 105, or 1.25 × 106 cells per mouse) with serial injections of rhIL-7-hyFc on days +1, +15, and +29 (n = 5 mice per group). The
top panels represent overall survival, while the bottom panels show serial tumor burden measurements (each line represents one mouse). p Values
were calculated using two-sided Wilcoxon test (UCART19 1.25 × 106 + rhIL-7-hyFc vs. UCART19 1.25 × 106 only, p = 0.0039). Source data are
provided as a Source data ﬁle. **p ≤ 0.01.

cell phenotype (Fig. 8e). Of note, cluster 10 exhibited a high
exhaustion score but also maintained expression of GZMK, TIGIT
and PDCD1, supportive of an exhausted-like memory state17
(Fig. 8e, f). Additionally, in clusters 0 and 1 that were more highly
represented at week 4, increased expression of IL7R, GZMB,
S100A4 and persistent high expression of PTPRC was observed,
providing further evidence that effector memory phenotypes are
maintained by in vivo administration of rhIL-7-hyFc (Fig. 8g).
10

Discussion
Enhancement of CAR T cell activity has the potential to improve
patient outcomes by reducing target positive relapse in patients with
CD19+ B cell malignancies. We show that adding rhIL-7-hyFc to
CAR T cells improves T cell expansion, persistence, and anti-tumor
activity, both with human CAR T cells targeting CD19 or CD33 in
an NSG xenograft model and with murine CAR T cells targeting
CD19 in two different strains of immunocompetent mice.

NATURE COMMUNICATIONS | (2022)13:3296 | https://doi.org/10.1038/s41467-022-30860-0 | www.nature.com/naturecommunications

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-022-30860-0

IL-7 is well known to promote T cell proliferation and expand
the T cell repertoire. Clinical trials exploring the use of rhIL-7 for
a variety of indications have shown that it is well tolerated and
increases T cell numbers in human subjects18–22. However, one of
the factors limiting the development of rhIL-7 has been its short
half-life in vivo, necessitating frequent doses to maintain biological activity. We used a novel form of IL-7 that is fused to a

ARTICLE

hybrid Fc domain, extending its half-life in vivo23. In vitro studies
comparing rhIL-7-hyFc and rhIL-7 show that they have nearly
identical effects on CAR T cells, as both increases the potency and
duration of CAR T cell activity. While we have not performed
in vivo comparison studies, it is likely that rhIL-7 would also
mediate similar effects to rhIL-7-hyFc in this setting if given
frequently enough, but the convenience of the long-acting
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Fig. 7 In vivo rhIL-7-hyFc therapy enhances both the quantity and quality of CAR T cells. a–g Balb/c mice were given cyclophosphamide 250 mg/kg on
day −1, then 2 × 106 CD45.1+ UTD or mCART19 cells on day 0, followed by rhIL-7-hyFc on day +1. Spleens were harvested on days +7 and +14 after T
cell injection (n = 3/group). Bar graphs represent median values, with each data point representing one mouse. a Spleen sizes (left, day +14) and cell
numbers (right) were signiﬁcantly increased in mice given rhIL-7-hyFc. b Fractionation of spleen cell subsets shows that the majority of cells are derived
from the CD45.2+ recipient. c Absolute numbers of mCART19 cells were higher in the spleens of mice after rhIL-7-hyFc treatment. d Apoptosis was
reduced in mCART19 at day +14 with rhIL-7-hyFc. e Both UTD and mCART19 show marked proliferation in response to rhIL-7-hyFc on day +7, which is
better sustained at day +14 for mCART19. f, g On day +7 mCART19 was puriﬁed from spleens and subject to in vitro functional assays. f mCART19
cytotoxicity against A20 tumor cells was measured at various E:T ratios by BLI after 48 h of incubation. Each line represents mCART19 cells extracted from
one mouse. g Intracellular IFNγ and TNFα production of mCART19 was measured after 4 h of incubation with A20 tumor cells. h-j NSG mice received
5×105 RamosCBR-GFP followed by UCART19 treatment and rhIL-7-hyFc on days +1 and +15. Spleens were harvested from mice on day +28. h Spleens
harvested from rhIL-7-hyFc-treated mice were notably larger than controls. i, j Target cell viability was determined by FACS-based cytotoxicity assay of
UCART19 from day 0 (input) as compared to UCART19 derived from spleens of rhIL-7-hyFc treated mice. The original Ramos tumor cells (i) or an
independent CD19+ B cell line, Nalm6 cells (j) were incubated with CD34-puriﬁed UCART19 at E:T ratios ranging from 4:1 to 1:4 for 20 h. Bar graphs
represent median values, with each data point representing a technical replicate. All p values were determined by two-sided unpaired Student’s t test. p
Values and source data are provided in the Source data ﬁle. ns: not signiﬁcant, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.

formulation would make this the preferred agent when moving
into clinical studies in humans. On this note, we used a dose of
10 mg/kg rhIL-7-hyFc, to achieve maximum effect in these preclinical models. While it is likely that lower doses of rhIL-7-hyFc
would be equally effective, the 10 mg/kg dose in mice is equivalent to 813 ug/kg in humans, and current clinical trials with rhIL7-hyFc have used doses up to 1200 ug/kg, without any serious
adverse events24–26. Therefore, our preclinical dosing can
potentially be directly converted to equivalent dosing in human
subjects.
In vivo studies with both human and mouse CAR T cells
demonstrate that the addition of rhIL-7-hyFc can lead to a more
than ﬁvefold reduction of CAR T cell numbers required for
biologic activity, with improved anti-tumor function and longer
persistence. These ﬁndings are signiﬁcant as currently CAR
T cells are an autologous therapy, and the potency of each
patient’s CAR T cells can be quite variable6,27. While some
patients’ CAR T cells are effective against tumors by themselves,
the majority of patients have less robust T cell function, and the
addition of rhIL-7-hyFc may be able to achieve tumor regression
in these individuals who would otherwise have succumbed to
refractory disease. Additionally, if allogeneic CAR T cell products
advance to the clinic in the future, rhIL-7-hyFc can be used to
lower the minimum required dose of CAR T cells per patient,
which could be a cost-effective strategy to overcome the ﬁnancial
toxicity of this therapy.
Given the potency of rhIL-7-hyFc to enhance CAR T cell
numbers, we elected to use gene-edited TCR deﬁcient CAR T cells
to eliminate the confounding effects of xenogeneic GVHD in our
preclinical mouse xenograft models. In terms of clinical translation, either autologous CAR T cells or allogeneic TCR deﬁcient
CAR T cells are used for patient care, so GVHD is not a concern.
However, NSG mouse models fail to address the potential for host
versus graft effect, speciﬁcally the concern that rhIL-7-hyFc may
contribute to host rejection of CAR T cells, which can occur even
in the autologous setting by immune responses directed against
the CAR28. Therefore, we also tested rhIL-7-hyFc in immunocompetent mouse models, using congenic CD45.1+ mCART19
containing GFP as a marker gene. While rhIL-7-hyFc induced a
preeminent expansion of endogenous lymphocytes, this did not
lead to rejection of CAR T cells, as mCART19 persisted for many
weeks and also mediated prolonged B cell aplasia up to 100 days
after initial T cell injection. While the T cells themselves would
not be foreign to the host, the presence of the synthetic CAR
construct and GFP could theoretically lead to rejection, and so the
persistence of CAR T cells in this setting was reassuring in that
regard.
12

Importantly, we did not see any evidence of toxicity with the
combination of mCART19 and rhIL-7-hyFc in the immunocompetent mice. Additionally, murine CAR T cell numbers in
immunocompetent mice did not reach the astronomical levels
seen with human CAR T cells in NSG mice after rhIL-7-hyFc.
The NSG model provides proof of principle that this reagent is
effective on human CAR T cells in vivo, but the lack of endogenous lymphocytes in these mice is likely responsible for the
massive expansion of CAR T cells, and in human subjects, the
kinetics of CAR T cell expansion is expected to be more akin what
was seen in the immunocompetent mice.
The ability of IL-7 to promote T cell memory is attractive to
those working in the CAR T cell ﬁeld. Culture of CAR T cells with
IL-7 and IL-15 during manufacturing has been shown to enhance
T cell differentiation toward a central memory (Tcm) phenotype,
enhancing the persistence and anti-tumor efﬁcacy of CAR T cells
in vivo and prolonging survival in murine models of B-ALL29.
We postulated that rhIL-7-hyFc would mediate enhanced CAR T
cell function and anti-tumor activity through the preferential
expansion and enhanced persistence of Tcm populations. However, contrary to our expectations, both human and murine CAR
T cells displayed a predominantly effector memory (Tem) phenotype after in vivo rhIL-7-hyFc treatment. In the murine model,
we were able to compare the response of endogenous T cells and
CAR T cells to rhIL-7-hyFc. For endogenous T cells, the effects of
rhIL-7-hyFc were approximately equivalent between CD4+ and
CD8+ T cells, and led to preferential increase of memory T cells.
However, in CAR T cells the effects of rhIL-7-hyFc were most
prominent in the CD4+ effector cells. These differences may be
due to the inherent bias of CAR T cells towards effector cells that
are ampliﬁed by the presence of antigen-positive target cells
providing additional activation and proliferation signals in vivo.
Functional assessment of CAR T cells after rhIL-7-hyFc in vivo
demonstrated better protection against tumor rechallenge and
prolonged B cell aplasia as compared to CAR T cells alone,
indicating that rhIL-7-hyFc does enhance immune protection,
despite the absence of phenotypic Tcm generation.
Transcriptional analysis of UCART19 exposed to rhIL-7-hyFc
in vivo by scRNAseq revealed overrepresentation of both CD4+
and CD8+ effector memory T cell subsets (clusters 0 and 1), as
characterized by high expression of S100A4 and low expression of
CCR7 and CD62L. By week 4, clusters 0 and 1 represented the
majority of UCART19, with the expression of granzyme B and
IL-7Rα increasing over time within these clusters. Additionally, T
cell exhaustion status, as measured by expression of inhibitory
receptors, decreased over time when UCART19 was exposed to
rhIL-7-hyFc treatment. Based on this data, it is conceivable that
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rhIL-7-hyFc therapy may prevent CAR T cell dysfunction and
propagate a highly functional CAR T phenotype in vivo.
Other groups have adopted different strategies to enhance CAR
T cell function using the IL-7 signaling pathway. These approaches range from engineering CAR T cells to secrete IL-730,31,
adding inverted cytokine receptors in which the external domain
from IL-4α is fused to the internal signaling domain from IL7Rα32, and expressing a constitutively active IL-7Rα33. However,
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genetically engineering IL-7 signaling into T cells may lead to
uncontrolled T cell expansion and proliferation, which may
exacerbate CAR T cell toxicities such as cytokine release syndrome (CRS) and neurotoxicity, or even result in malignant
transformation of the T cells themselves. Using rhIL-7-hyFc with
CAR T cells provides opportunities to modify both the timing
and dose of the reagent to mitigate toxicities while still enhancing
therapeutic efﬁcacy. Furthermore, rhIL-7-hyFc-mediated
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Fig. 8 Single-cell RNA sequencing reveals that rhIL-7-hyFc preferentially expands IL-7Rα effector memory CAR T cells. a RamosCBR/GFP bearing NSG
mice (5 × 105 cells IV on day −4) received rhIL-7-hyFc on days +1 and +15 following 1 × 106 UCART19 injection. Spleens were harvested on days +14 and
+28, and UCART19 cells enriched using CD34+ magnetic selection were subject to single-cell RNA-sequencing. b Proportion of cells (size of circle) for
each single-cell cluster (Seurat) were broken down by treatment group (Input, Week 2, and Week 4). c UMAP representation of the single-cell RNAsequencing data, combined from all samples, colored and labeled by Seurat clusters. d Downsampled objects (n = 2000 cells for each treatment group)
separated by treatment week. e Downsampled objects (n = 2000 cells for each treatment group) colored by exhaustion score, calculated based on the
expression of genes known to be involved in T cell exhaustion (CTLA4, PDCD1, LAG3, HAVCR2, CD160, CD244, and TIGIT). Dark purple indicates a higher
exhaustion phenotype, and light blue indicates a less exhaustive phenotype. f Gene expression analysis of relevant T cell genes and pathways for each
Seurat cluster. The size of the circle indicates the percentage of cells with the expression of each gene and color indicates average expression across the
cells in that unique cluster. g Focused view of clusters 0 and 1 showing increased expression of the genes IL-7Rα, GZMB, S100A4, and PTPRC across
treatment groups.

enhancement of endogenous recipient T and NK cell proliferation
and function may provide additional anti-tumor beneﬁt.
In summary, we demonstrate that rhIL-7-hyFc can dramatically enhance CAR T cell expansion, persistence, and anti-tumor
activity in vivo, resulting in signiﬁcant improvement in survival in
mice. These results are being pursued further in an ongoing
clinical study (NCT05075603) to test the impact of rhIL-7-hyFc
on CD19-targeting CAR T cells in humans.
Methods
rhIL-7-hyFc. rhIL-7-hyFc was generously provided by NeoImmuneTech, Inc.
CAR constructs. The CAR19 construct was synthesized using the immunoglobulin
heavy and light chain sequences of anti-human CD19 antibody clone FMC63, and
cloned into PLVM lentiviral vector containing a third-generation CD28-4-1BBCD3ζ CAR construct. Additionally, the vector was modiﬁed to express human
CD34 via a P2A peptide. Expression of CD34 allowed for detection of the CAR
following viral transduction, as well as puriﬁcation of CAR positive cells using antihuman CD34 positive magnetic beads, as previously described34. The CAR33-41BB-CD3zeta construct was synthesized based on a previously published
sequence35 and also cloned into the PLVM lentiviral vector.
The mouse CAR19 vector was kindly provided by Dr. M. Sadelain (Memorial
Sloan-Kettering Cancer Center, New York, NY). The CAR sequence is based on the
immunoglobulin heavy and light chain sequences of anti-mouse CD19 antibody
clone 1D3, followed by the mouse CD8 transmembrane region, mouse CD28 signal
transduction domain, and the mouse CD3 cytoplasmic domain. Additionally, to
facilitate the tracking of CAR transduced cells, GFP was linked to the CAR
construct by a glycine-serine linker. This construct was cloned into the SFG
retroviral vector10. All plasmids were veriﬁed by sequencing across the CAR
construct prior to virus production.
Viral vector production. Lentivirus for human T cell transduction was generated
by transfecting the Lenti-X 293T cell line (Clontech, 632180) with the PLVM CAR
vector and packaging plasmids, pMD.Lg/pRRE, pMD.G, and pRSV.Rev using
Lipofectamine 2000 (ThermoFisher Scientiﬁc, 11668500). The virus was harvested
24 and 48 h post transfection, ﬁltered to remove cell debris, concentrated by
ultracentifugation for 90 min at 25,000 r.p.m. at 4 °C, and stored at −80 °C in single
use aliquots.
Retrovirus for murine T cell transduction was generated by transfecting the
Lenti-X 293T cells with the SFG CAR vector and the Ecopac packaging plasmid
using Lipofectamine 2000. The virus was harvested 24 and 48 h post transfection,
ﬁltered to remove cell debris, stored at −80 °C, and thawed immediately prior to
use. Both human and murine CAR T cell activities were veriﬁed by in vitro
cytotoxicity assays against target-positive and target-negative cells prior to in vivo
experiments.
Human CAR T cells. TRAC gRNA was commercially synthesized (Trilink Biotechnologies San Diego, CA), incorporating 2′-O-methyl and 3′ phosphorothioate
(ps) bases at the three terminal bases of the 5′ and 3′ ends of the gRNA to protect
from nuclease activity36. Streptococcus pyogenes Cas9 (spCas9) mRNA (5meC, Ψ)
was also purchased from Trilink Biotechnologies. The full RNA guide sequence is
as follows, with target sequence underlined: 5′_2′OMe(G(ps)A(ps)G(ps))AAUCA
AAAUCGGUGAAUGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGC
UAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC2′OMe
(U(ps)U(ps)U(ps) U 3′.
T cells obtained from healthy human donors and were cultured in RPMI
complete media (RPMI with 10% FBS, 1% PenStep, 1% Glutamax, 2 mM HEPES
and 50 nM 2-Mecaptoethnol), supplemented with 50 U/mL IL-2, 10 ng/ml IL-15
and 10 ng/ml IL-7. CD3/CD28 Dynabeads (ThermoFisher Scientiﬁc, 40203D) were
used to activate T cells, with a bead to cell ratio of 3:1. On day +2 post-activation,
14

beads were removed and 1 × 107 T cells were electroporated in 100 µl of MaxCyte
EP buffer using 15 µg spCas9 mRNA and 20 µg of TRAC gRNA using the Maxcyte
GT, program “Expanded T cell #2”. Cells were transduced with lentiviral particles
in the presence of 6 µg/ml polybrene (Sigma Aldrich. St Louis MO) at 1–24 h post
electroporation. Cells were expanded for an additional 8 days, then depleted for
residual non-edited TCR+ T cells using CD3+ magnetic bead-based on the
AutoMacs (Miltenyi) per manufacturer protocol. Cells were either used fresh or
frozen and thawed as needed for the experiments.
Mouse CAR T cells. Spleens were harvested from CD45.1+ mice and enriched for
T cells using the Miltenyi Pan T cell isolation kit II (#130-095-130) per manufacturer protocol. Puriﬁed T cells were activated on the same day of harvest (=day
0) with CD3/CD28 Dynabeads (Gibco, 11453D) at 1:1 bead to cell ratio, and
cultured in RPMI complete media supplemented with 10 U/ml IL-2 and 10 ng/ml
IL-15. On days +1 and +2 post-activation, T cells were spinoculated with retroviral
supernatant on plates coated with Retronectin (Clontech, T100B). On day +3,
beads were removed and %GFP was measured by ﬂow cytometry to assess the
efﬁciency of gene transfer. Cells were either used fresh or frozen and thawed as
needed for the experiments.
Cell lines. Ramos (CRL-1596), NALM6 (CRL-3273), U937 (CRL-1593.2), and A20
(TIB-208) cell lines were obtained directly from ATCC. The cell lines were
mycoplasma tested and antigen expression was conﬁrmed by ﬂow cytometry prior
to use. PLVM EF1αCBR-GFP lentivirus was used to transduce cells with the CBRGFP construct, followed by single-cell cloning to establish the RamosCBR-GFP
NALM6 CBR-GFP, U937CBR-GFP, and A20CBR-GFP cell lines.
The 9523 murine acute promyelocytic leukemia (APL) cells were previously
generated in our laboratory by knocking in the human PML-RARa cDNA into the
5′ regulatory sequence of the cathepsin G locus, which produces a high-penetrance
APL phenotype in 90% of mice37. Tumor cells were subsequently immortalized by
serial propagation in vitro. Murine CD19 expression was added to 9523 cells by
lentiviral gene transfer, followed by single cell cloning to establish a pure cell
population of 9523CD19.
In vitro expansion assay. RamosCBR-GFP (0.5 × 106) and UCART19 (1 × 106) were
plated in a 24-well plate in RPMI complete media with no cytokine supplementation. rhIL-7 or rhIL-7-hyFc was added to the culture to a ﬁnal concentration
of 10 ng/ml, 100 ng/ml, or 1000 ng/mg. Seven days later, cells were harvested and
counted, and ﬂow cytometry was performed to ensure no residual tumor cells
remained in the culture. CAR T cells were then re-plated at a 2:1 effector to target
(E:T) ratio in fresh media containing the same concentrations of rhIL-7 or rhIL-7hyFc as the initial culture. On day 14 CAR T cells were harvested and analyzed by
ﬂow cytometry and single-cell cytokine analysis.
Flow cytometry. Cell lines and T cells from in vitro experiments were directly
transferred into ﬂow cytometry tubes and washed once prior to staining with
ﬂuorescently labeled antibodies for 15 min at room temperature. For peripheral
blood evaluation, 50 μl was added to 2 ml of RBC lysis buffer in ﬂow cytometry
tubes and incubated for 10 min at room temperature, followed by a single wash and
addition of Fc block (BioLegend #101320), then antibody staining. Spleens were
macerated over a 70 um cell strainer using the piston from a 3 ml syringe to create
single cell suspensions, after which 1-2e6 cells were transferred to ﬂow cytometry
tubes and washed once prior to Fc block and antibody staining.
All samples were run on either an Attune NxT Flow Cytometer (Thermo Fisher
Scientiﬁc) or a ZE5 (Yeti) cytometer (Bio-Rad). Data analysis was performed using
FlowJo v10.6.1 (Tree Star Inc.) or FCS Express v7.08.0018 (De Novo Software). The
following reagents were used to evaluate human CAR T cell phenotype (all
antibodies are against human antigens): CD34-PE (Beckman Coulter, IM1459U,
dilution 1:30), LIVE/DEAD ﬁxable yellow (Thermo Fisher Scientiﬁc, L34967,
dilution 1:500), Annexin V-APC (BD Biosciences, 550474, dilution 1:10), Ki-67APC (eBioscience, 17-5698-82, dilution 1:10), CD4-FITC (BioLegend, 300506,
dilution 1:200), CD8-BV421 (BioLegend, 301036, dilution 1:80). For UCART33 we
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used ﬂuorescently labeled CD33 protein (Sino Biological, 12238-H05H-100,
dilution 1:500) to detect CAR T cells, as this construct did not contain the human
CD34 tag. Human T cell memory phenotype was evaluated using the following
antibodies: CD45RO-BV421 (BioLegend, 304224, dilution 1:100), CD45RA-APC/
Cy7 (Biolegend, 304128, dilution 1:100), CCR7-AF647 (BioLegend, 353218,
dilution 1:100), CD3-BV786 (BioLegend, 317330, dilution 1:100), CD4-BV650
(BioLegend, 317436, dilution 1:100), CD8-AF700 (BioLegend, 300922, dilution
1:400).
Evaluation of murine peripheral blood was performed using the following
antibodies (all against mouse antigens): CD45.1-PE/Cy7 (eBioscience, 25-0453-82,
dilution 1:200), CD45.2-APC/ef780 (eBioscience, 47-0454-82, dilution 1:100),
CD19-APC (BioLegend, 115512, dilution 1:400), Gr-1-BV605 (BioLegend, 108440,
dilution 1:500), CD3-PE (BioLegend, 100206, dilution 1:100), and LIVE/DEAD
ﬁxable yellow (Thermo Fisher Scientiﬁc, L34967, dilution 1:500).
Detailed phenotyping of murine peripheral blood was performed using the
following antibodies (all against mouse antigens): CD4-BUV395 (BD, 563790,
dilution 1:400), LIVE/DEAD ﬁxable blue (Thermo Fisher Scientiﬁc, L23105,
dilution 1:500), CD11b-BUV661 (BD, 565080, dilution 1:500), B220-BUV737 (BD,
612838, dilution 1:500), CD44-BV421 (BD, 563970, dilution 1:500), CD8-BV510
(BioLegend, 100752, dilution 1:500), CD45.2-BV605 (BioLegend, 109841, dilution
1:500), Ly6G-BV650 (BioLegend, 127641, dilution 1:500), CD16/32-BV711
(BioLegend, 101337, dilution 1:500), CD49b-BV785 (BD, 740895, dilution 1:500),
CD19-PerCP/C5.5 (BioLegend, 152405, dilution 1:500), Ly6C-PE-CF594 (BD,
562728, dilution 1:1000), CD45.1-PE/Cy5 (eBioscience, 15-0453-82, dilution
1:1000), CD127-PE/Cy7 (eBioscience, 25-1273-82, dilution 1:1000), CD3-APC (BD,
553066, dilution 1:500), CD62L-APC/Cy7 (BioLegend, 104428, dilution 1:500).
Single-cell cytokine proﬁling of UCART19. Single-cell cytokine production was
measured using an IsoLight System (IsoPlexis). UCART19 cells were labeled with
Violet stain A according to the manufacturer’s protocol. Cells were incubated with
targets at a 1:1 E:T ratio for 20 h. After stimulation, residual target cells were
depleted with CD19 biotin microbeads using the Miltentyi Automacs according to
the manufacturer’s instructions. Cells were stained Alexa Fluor 647-conjugated
anti-human CD8 (IsoPlexis) at room temperature for 20 min and loaded onto an
IsoCode chip (IsoPlexis). Each IsoCode chip contains ~12,000 microchambers prepatterned with a full copy of 32-plex antibody array including Effector: Granzyme
B, TNFα, IFN-γ, MIP1α, Perforin, TNFβ; Stimulatory: GM-CSF, IL-2, IL-5, IL-7,
IL-8, IL-9, IL-12, IL-15, IL- 21; Chemo-attractive: CCL11, IP-10, MIP-1β,
RANTES; Regulatory: IL-4, IL-10, IL-13, IL-22, sCD137, sCD40L, TGFβ1;
Inﬂammatory: IL-6, IL-17A, IL-17F, MCP-1, MCP-4, IL-1β. The polyfunctional
proﬁle (2+ proteins per cell) of single cells was evaluated by IsoSpeak software
version 2.7.0.0.
Mice. All mice used in these studies were aged 6–12-week-old males purchased
from Jackson Laboratories (Bar Harbor, ME): NOD-SCID-IL2Rγ−/− (NSG)
(#005557), C57BL/6J (#000664), BALB/cJ (#000651), B6.SJL-Ptprcaa Pepcb/BoyJ
(B6-CD45.1) (#002014), CByJ.SJL(B6)-Ptprcaa/J (Balb/c-CD45.1) (#006584). All
animal experiments were performed according to an animal protocol approved by
the Institutional Animal Care and Use Committee at Washington University
School of Medicine. All experimental mice were co-housed within speciﬁc
pathogen free facilities at Washington University School of Medicine and maintained on ad libitum water and standard chow (LabDiet 5053; Lab Supply, Fort
Worth, TX), with a 12 h light/dark cycle and a temperature range of 68–74°F with
40–60% humidity. Mice were euthanized if they exhibited signs of illness or discomfort (tumor growth ≥2 cm, weight loss ≥20%, hind limb paralysis, lethargy,
hunched posture), using carbon dioxide asphyxiation followed by cervical
dislocation.
In vivo mouse xenograft experiments. NSG mice were injected intravenously
(IV) via the lateral tail vein with 5 × 105 RamosCBR-GFP or 5 × 104 U937 CBR-GFP on
day −4. On day 0, 1 × 106 UCART cells were injected IV. Mice received 10 mg/kg
rhIL-7-hyFc subcutaneously (SC) on days +1, +15, and +29.
To track tumor growth in vivo, mice were injected intraperitoneally with 50 μg/
g D-luciferin (Goldbio, eLUCNA), and bioluminescence was measured using an
AMI HT optical imaging system (Spectral Instruments). Images were analyzed
using Aura 4.0 In Vivo Imaging Software (Spectral Instruments).
In vivo immunocompetent mouse experiments. C57BL/6 mice were injected IV
with 5 × 104 9523CD19 cells on day −3, followed by intraperitoneal (IP) injection of
cyclophosphamide (Cayman, 13849) 250 mg/kg on day −1, then injected IV with
6 × 106 UTD or mCART19 (manufactured from CD45.1+ C57BL/6 mice) cells on
day 0. Mice were then given 10 mg/kg rhIL-7-hyFc SC on days +1, +15, and +29.
Mice were bled via facial vein every 4–6 days, and total white blood cell (WBC),
hemoglobin, and platelet counts were measured using a Hemavet 950 analyzer
(Drew Scientiﬁc). Absolute numbers of circulating leukocyte subsets were calculated by multiplying the WBC counts by the frequency of each cell type as measured by ﬂow cytometry.
For in vivo mCART19 dose titration, Balb/c mice were injected IV with 1 × 106
A20 cells on day −4, followed by cyclophosphamide IP on day −1, then different
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doses of mCART19 (manufactured from CD45.1+ Balb/c mice) on day 0, followed
by 10 mg/kg rhIL-7-hyFc SC on days +1, +15, and +29. Serial WBC counts and
leukocyte subsets were measured as above.
To evaluate the anti-tumor activity of mCART19, Balb/c mice were irradiated
with 600 cGy on day −8, followed by injection with either 5 × 105 A20CBR-GFP cells
IV, or 1 × 106 A20CBR-GFP cells SC on day −7. Mice were then given IV injections
of 5 × 105 mCART19 on day 0 and 10 mg/kg rhIL-7-hyFc SC on days +1 and +15.
Tumor burden was followed by bioluminescent imaging as above.
To harvest mCART19 after rhIL-7-hyFc treatment in vivo, Balb/c mice were
given cyclophosphamide 250 mg/kg IP on day −1 followed by 5 × 105 mCART19
cells IV on day 0. Mice were euthanized on day 7 and day 14 after mCART19, and
spleens were harvested and macerated into single cell suspension using a 40 μm
nylon cell strainer. Cells were then counted and analyzed by ﬂow cytometry to
assess leukocyte subsets. Adoptively transferred CD45.1+ cells from the spleens
were puriﬁed using CD45.1-biotin (BioLegend, 110703) and anti-biotin microbeads
(Miltenyi, 130-090-485), using the AutoMACS per manufacturer protocol.
In vitro UCART19 cytotoxicity assay. NALM6CBR-GFP or RamosCBR-GFP target
cells were seeded at a density of 25,000 cells per well in a 96-well plate in RPMI
complete media. UCART19 cells were puriﬁed from the spleens of NSG mice on
day +28 by labeling with CD34-PE antibody (Beckman Coulter, IM1459U) followed by anti-PE microbeads (Miltenyi, 130-048-801) and selecting bead-bound
cells on the AutoMACS. Cryopreserved UCART19 input cells from Day 0 were
used as a control. UCART19 cells were co-cultured with target cells at E:T ratios
ranging from 4:1 to 1:4 at 37 °C for 20 h. Absolute cell counts of viable target cells
were quantiﬁed by ﬂow cytometry using 7-aminoactinomycin D and GFP.
In vitro mCART19 cytotoxicity assay. A20CBR-GFP target cells were seeded at a
density of 50,000 cells per well in a black 96 well plate in RPMI complete media.
mCART19 cells puriﬁed from spleens were co-cultured with target cells at E:T ratios
ranging from 4:1 to 1:4 at 37 °C for 48 h. Residual tumor cells were quantiﬁed by
bioluminescent imaging of the plate after adding 125ug/ml of D-luciferin (Goldbio,
eLUCNA) using an AMI HT optical imaging system (Spectral Instruments). Percent
cell lysis was calculated as follows: [1 − (BLItreated/BLIuntreated)] × 100. All data
points are technical duplicates.
In vitro mCART19 intracellular cytokine staining. In all, 2 × 105 mCART19
effector cells and 1 × 106 A20 target cells were co-cultured for 4 h at 37 °C in the
presence of brefeldin A (BD Biosciences, 555029). Cells were then harvested and
stained with LIVE/DEAD ﬁxable yellow (Thermo Fisher Scientiﬁc, L34967) and
CD3-APC/Cy7 (BioLegend, 100221), then treated with FIX & PERM cell permeabilization kit (ThermoFisher Scientiﬁc, GAS003) with the following antibodies
against mouse cytokines: IFNg-PE (BioLegend, 505807), TNFa-APC (BioLegend,
506307).
Single-cell RNA sequencing. For xenograft tumor modeling in vivo, we injected
NSG mice with 5 × 105 RamosCBR-GFP cells 4 days before UCART19 (1 × 106 cells)
infusion. Mice were treated with rhIL-7-hyFc (10 mg/kg SC) or vehicle on days +1,
and +15 post UCART19 infusion. On day +14 and day +28, mice were sacriﬁced
and CAR-T cells were enriched from the spleen using CD34+ magnetic enrichment (Miltenyi). For the rhIL-7-hyFc treated groups (“week2” and “week4”), cells
obtained from ﬁve mice per group were pooled on day +14 and day +28. For the
Vehicle on control groups (“C1” and “C2”), cells were pooled from ﬁve mice per
group on day +14. Additionally, UCART19 cells were harvested prior to infusion
into mice on the day of UCART19 treatment (“Input”). Enriched CAR-T cells were
resuspended in PBS containing 0.04% BSA, at a concentration of 1 × 106/ml, and
submitted to the McDonnell Genome Institute for 3′ scRNA-seq. Utilizing the 10×
Genomics Chromium Single Cell 3’v3 Library Kit and Chromium instrument,
approximately 16,500–20,000 cells were partitioned into nanoliter droplets to
achieve single-cell resolution for a maximum of 10,000 individual cells per sample.
The resulting cDNA was tagged with a common 16nt cell barcode and 10nt Unique
Molecular Identiﬁer during the RT reaction. Full-length cDNA from poly-A
mRNA transcripts was enzymatically fragmented and size selected to optimize the
cDNA amplicon size (approximately 400 bp) for library construction (10x Genomics). The concentration of the 10x single cell library was accurately determined
through qPCR (Kapa Biosystems) to produce cluster counts appropriate for the
HiSeq 4000 or NovaSeq 6000 platform (Illumina). 26 × 98 bp sequence data were
generated targeting 50K read pairs/cell, which provided digital gene expression
proﬁles for each individual cell. Samples were aligned to the human and mouse
genome (refdata-gex-GRCh38_and_mm10-2020-A) and demultiplexing, barcode
processing and alignment were performed using CellRanger Single-Cell Software
Suite v4.0.0. Cells were ﬁltered using EmptyDrops[40] and further ﬁltered to only
maintain cells with <20% human mitochondrial DNA content and with a minimum of at least 200 and maximum of 20,000 genes expressed. Finally, to address
multiplets of human and mouse cells, cells with <95% human mapped reads were
ﬁltered out. After ﬁltering, <50 cells were maintained from the control arms (C1
and C2) and these samples were removed from downstream analyses. All singlecell data across all samples were merged together using Seurat merge and anchor
functions.
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Statistical analysis. Data plots were generated using GraphPad Prism 9.1.0 (La
Jolla, CA). The determination of sample size and data analysis for this study
followed the general guideline for animal studies38. The distributions of time-todeath were described using Kaplan–Meier product limit method and compared by
the generalized Wilcoxon test which is less sensitive to the assumption of proportional hazards. All the other in vivo data were summarized using means and
standard deviations. The differences were compared using two-sample Student’s t
test, one-way analysis of variance, or linear mixed model for repeated measurement
data as appropriate, followed by post hoc multiple comparisons for between-group
differences of interest. Based on the law of diminishing returns, Mead recommended that a pilot study with a sample size of 10–20 subjects would be adequate
to estimate preliminary information39. The normality of data was assessed graphically using residuals and logarithm transformation was performed as necessary
to better satisfy the normality and homoscedasticity assumptions. All analyses were
two-sided and signiﬁcance was set at a p value of 0.05. The statistical analyses were
performed using SAS 9.4 (SAS Institutes, Cary, NC).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
All data generated from this study are available within the paper and its Supplementary
Information. Source data are provided with this paper. Human and mouse reference
genomes (refdata-gex-GRCh38-and-mm10-2020-A) required for CellRanger can be
downloaded from 10× Genomics (https://support.10xgenomics.com/single-cell-geneexpression/software/downloads/latest). The scRNA-seq data generated in this study has
been deposited into the NCBI sequence read archive (SRA) database under BioProject
accession PRJNA789884.

Code availability
Custom code was not generated for this manuscript. The following publicly available
pipelines were utilized for analysis: standard preprocessing and quality control of scRNAseq data was based on Seurat Guided tutorials (https://satijalab.org/seurat/articles/
pbmc3k_tutorial.html), splicing related analysis were performed by sjcount (https://
github.com/pervouchine/sjcount), and monocle trajectory analysis was performed using
standard tutorials (https://cole-trapnell-lab.github.io/monocle3/docs/trajectories/).
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